Prestige Consumer Healthcare Reports Q4 2026 Miss, Eyes Recovery Through Acquisitions and Clear Eyes Supply Improvements

Prestige Consumer Healthcare Inc. (NYSE: PBH) reported a softer fourth quarter for fiscal 2026, with revenue and adjusted earnings missing Wall Street expectations, while management pointed to supply constraints, eye care production limits, and international shipping disruptions as key pressures.

The company posted fourth-quarter revenue of $281.6 million, down 5.0% from $296.5 million a year earlier. Adjusted diluted earnings per share came in at $1.23, below the prior-year level of $1.32 and below analyst expectations cited by Seeking Alpha.

Q4 Results Show Pressure From Eye Care Supply Constraints

The biggest drag on the quarter came from Prestige’s Eye & Ear Care category, especially the company’s limited ability to meet demand for Clear Eyes. Management said the revenue decline also reflected a tough comparison with last year, when some orders were pulled forward into the prior fourth quarter.

Despite the sales decline, reported net income improved to $53.9 million, compared with $50.1 million in the same quarter last year. Diluted EPS rose to $1.13 from $1.00. However, on an adjusted basis, net income fell to $58.5 million from $65.9 million, showing that the operating environment remained difficult.

Full-Year Fiscal 2026 Revenue Declines

For the full fiscal year ended March 31, 2026, Prestige reported revenue of $1.0887 billion, down 4.3% from $1.1378 billion in fiscal 2025. The company said the yearly decline was mainly tied to the Clear Eyes supply issue, which limited its ability to serve customer demand.

Fiscal 2026 net income was $190.3 million, compared with $214.6 million in the prior year. Reported diluted EPS was $3.91, while adjusted diluted EPS was $4.38.

North America Segment Takes the Biggest Hit

Prestige’s North American OTC Healthcare segment generated fourth-quarter revenue of $234.5 million, down from $248.9 million a year earlier. The company again pointed to lower Eye & Ear Care sales, mainly due to Clear Eyes production limits. For the full year, North American OTC revenue fell to $913.6 million from $960.0 million.

International Business Faces Shipping Disruptions

The International OTC Healthcare segment posted fourth-quarter revenue of $47.1 million, slightly below $47.6 million last year. Prestige said the segment was affected by shipping disruptions in the Middle East and weaker Eye & Ear Care sales. For fiscal 2026, international revenue was $175.1 million, down from $177.8 million.

Cash Flow Remains a Bright Spot

Even with weaker sales, Prestige continued to produce strong cash flow. Operating cash flow rose to $257.6 million for fiscal 2026, while non-GAAP free cash flow increased to $246.4 million. Management described this cash generation as an important strength of the business model.

The company also repurchased 2.3 million shares during fiscal 2026 for about $156 million. At year-end, Prestige had net debt of roughly $900 million and a covenant-defined leverage ratio of 2.6 times.

LaCorium Acquisition Adds Skin Care Growth Platform

Alongside its earnings report, Prestige announced a definitive agreement to acquire LaCorium Health for about $150 million in cash. LaCorium is an Australian therapeutic skin care company known for brands such as Dermal Therapy, Flexitol, and Crampeze.

LaCorium generated about $40 million in trailing twelve-month revenue through February 28, 2026, and Prestige expects the business to generate about $12 million in EBITDA, including expected synergies after integration. The deal is expected to close in the second quarter of fiscal 2027.

Breathe Right Deal Could Reshape Portfolio

Prestige is also preparing to acquire the Breathe Right brand in a larger transaction valued at about $1.045 billion. Reuters reported that Breathe Right generated about $200 million in revenue and $95 million in core profit in 2025, and the transaction is expected to close in the first half of 2027.

If completed, Breathe Right would become one of the company’s most important brands and expand Prestige into a stronger position within nasal and respiratory care. This could help balance weakness in eye care and broaden the company’s category exposure.

Fiscal 2027 Outlook Points to Modest Organic Growth

For fiscal 2027, Prestige expects revenue of $1.10 billion to $1.121 billion, organic revenue growth of 1% to 3%, adjusted diluted EPS of $4.42 to $4.51, and free cash flow of at least $250 million.

Management said the forecast reflects momentum in several strategic brands, but also includes caution around Clear Eyes supply recovery and a still-volatile consumer backdrop. The company expects to update guidance after the Breathe Right and LaCorium acquisitions close.

Medium-Term Outlook Looks More Positive

Looking beyond fiscal 2027, Prestige said it expects its expanded brand portfolio and improving eye care capacity to support stronger growth. The company projected about 10% annual revenue CAGR, around 8% EPS CAGR, and close to $900 million in cumulative free cash flow over the next three years.

This medium-term outlook suggests management believes the current weakness is temporary. The key question for investors is whether Prestige can restore Clear Eyes supply, integrate acquisitions smoothly, and maintain strong margins during a period of cautious consumer spending.

Investor Takeaway

Prestige Consumer Healthcare’s Q4 fiscal 2026 report was mixed. The headline numbers missed expectations, and revenue declined due to clear operational issues. Still, the company remains profitable, cash flow is solid, and management is using acquisitions to build a larger and more diversified OTC healthcare portfolio.

For investors, the story now depends on execution. If Prestige can improve Clear Eyes production, close and integrate LaCorium and Breathe Right, and keep free cash flow strong, fiscal 2027 could mark the start of a recovery. However, if supply constraints or consumer weakness continue, growth may remain slower than management hopes.

#SlimScan #GrowthStocks #CANSLIM